Owkin partners with AstraZeneca to enhance gBRCA testing for breast cancer

FHS
October 4, 2024
11:35 am

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments —

January 8, 2024

Pieces Technologies Raises $25M to Expand GenAI Clinical Solutions

What You Should Know: – Pieces Technologies, a provider of clinical generative AI solutions that supports inpatient care teams secures $25M in growth financing. –

September 12, 2024

Global health boost as new vaccine SKYTyphoid gains WHO prequalification

SK bioscience and the International Vaccine Institute (IVI) announced today that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has

February 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.